The U.S. Food and Drug Administration (FDA) approved 6 CAR T cell (CAR-T) products, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel) in the last 5 years. CAR T-cell therapy significantly improved outcomes for patients with B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). However, recurrence and progression may occur after the initial response due to multiple mechanisms (Zeng and Zhang, 2022) [1]. Furthermore, CAR T-cell therapy is not broadly utilized in solid tumors due to various barriers. This review discusses the evolution of CAR T-cell therapies and how the “younger-generation” CAR T cells counteract these challenges to potentially broaden their applications in the future.
الاستشهاد بهذا المقال (APA)
Dongni, Y., Mia, G., Jingmei, H., Yang, Y., Xia, B., Mahmoud, A., Usama, G. (2022). Next-Generation Chimeric Antigen Receptor T-cells. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.56875/2589-0646.1035
